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ABSTRACT 
ASHLI FITZPATRICK: Secondary Metabolites Isolated from Perovskia atriplicifolia 
and Their In Vitro Binding Affinity for Human Opioid and Cannabinoid Receptors 
 
(Under direction of Dr. Stephen Cutler) 
 
 
 Plants and their natural products have been utilized for thousands of years in the 
treatment of many human diseases. Because of their structural diversity, natural products 
are ideal lead compounds for drug development. In this thesis, the natural products of the 
plant Perovskia atriplicifolia were investigated, specifically their in vitro binding affinity 
to receptors in opioid and cannabinoid classes. Extracts that demonstrated good selective 
opioid and cannabinoid receptor binding were subjected to bioassay-guided fractionation. 
Four active compounds were identified from the crude extract in Perovskia atriplicifolia: 
1) 5-hydroxy-3’,4’,6,7-tetramethoxy flavone, 2) 5,7-dihydroxy-3’,4’,6,-trimethoxy 
flavone, 3) 5-hydroxy-4’,6,7-trimethoxy flavone, and 4) 5,7-dihydroxy-4’,6,-dimethoxy 
flavone. Each compound exhibited good selective δ-opioid receptor binding affinity and 
was characterized as a flavanoid.  
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Background 
 
I. Natural Products as a Resource for Drug Discovery  
 
 Natural products, also known as secondary metabolites, refer to chemical 
compounds or substances produced by living organisms such as plants, animals, or 
microbes (Clement, 2005). Primary metabolites, which include glucose, DNA, and amino 
acids, are chemically identical in nearly all organisms and are required for normal 
development and growth of the organisms (Clement, 2005). Unlike primary metabolites, 
secondary metabolites are not directly required by an organism, are typically unique to a 
specific species or subset of a species, and can offer novelty in structure or function 
(Amsler et al., 2011). Secondary metabolites are synthesized primarily from the 
compounds acetate, mevalonate, shikimate, and various amino acids (Gao, 2010). 
Because these compounds are also used in the synthesis of essential primary metabolites, 
it is theorized that the excess compounds were utilized to create non-essential natural 
products (Gao, 2010). Natural products are created in nature and have naturally evolved 
with their producers, resulting in biological activity that is increasingly useful and 
effective (Gao, 2010). Natural product structures are extremely diverse and have high 
binding affinities to their specific receptor type (Gao, 2010). Because of their structural 
diversity and receptor binding activity, natural products are ideal bioactive lead 
compounds for drug development (Kingston, 2012).  
 Plants and their natural products have formed the foundation of complex traditional 
medicine systems and have been a major source of curative products for thousands of 
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years. Records indicate that hundreds of medicinal plants were utilized in Mesopotamia, 
dating back to the year 2600 BCE (Cragg and Newman, 2013). Several of these plant-
derived substances, ranging from Glycyrrhiza glabra (licorice) to Papaver somniferum 
(poppy juice) to Cupresses sempevirens (cypress), are still used today as treatments for 
coughs, colds, parasitic infections, and inflammation (Cragg and Newman, 2013). 
According to data retrieved by the World Health Organization (WHO), it is estimated that 
80% of the world, primarily in undeveloped countries, depends on traditional medicines 
for their primary health care, with 65% of that number specifically relying on plant-
derived medications (Cragg and Newman, 2005).   
  Natural products are also utilized in developed countries. Estimates indicate that 
over 50% of the most-prescribed drugs in the United States owe their beginnings to 
natural products, either through direct use of the plant or as a precursor in the design or 
synthesis of the drug (Cragg and Newman, 2005). Most anticancer and anti-infective 
drugs, however, are estimated to contain an even larger proportion of natural products 
(Kingston, 2012). The most popular natural-source anticancer drug, paclitaxel  (Fig. 1), 
was isolated from the bark of the Pacific yew tree, Taxus brevifolia, and was approved 
for use against ovarian cancer by the Food and Drug Administration (FDA) in 1992 
(NIH-NCI). Since then, the plant-derived drug has been utilized for the treatment of 
Kaposi’s sarcoma as well as breast and lung cancer and has become the best-selling 
cancer drug ever manufactured (NCI). Because of its tremendous success, many 
researchers attempted to develop similar chemical relatives of paclitaxel 1, resulting in 
the synthesis of two analogues, docetaxel and cabazitaxel (Cragg and Newman, 2013).  
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Chemical structure of paclitaxel 1 
 
Figure 1 
 
 
 Many other important drugs have been exploited from traditional medicinal plants. 
Vinblastine and vicristine, derivatives of from the Madagascar periwinkle, Catharanthus 
roseus, are also utilized in the treatment of cancer (Cragg and Newman, 2013). Ephedrine 
(1), a plant isolated from the plant Ephedra sinica, is the basis for anti-asthma agents 
salbutamol and salmetrol (Cragg and Newman, 2013). Reserpine (2), an antihypertensive 
agent isolated from the flowering plant Rauwolfia serpentina, is utilized for the treatment 
of snakebite (Crag and Newman, 2013). Tubocurarine (3), the muscle relaxant isolated 
from Chondrodendron and Curarea species, is used as an arrow toxin, curare, by 
indigenous groups in the Amazon (Cragg and Newman, 2013).  
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    Ephedrine (1)                         Reserpine (2)   
    
 
Tubocurarine (3) 
Some important natural products 
Figure 2  
 
  
 
	  5	  
It is apparent that natural products will continue to be an important source of 
novel structural leads and drugs, but despite their prevalence in the pharmaceutical 
industry, the surface of natural products has barely been scratched. Out of nearly 300,000 
species of vascular plants, only 15% have been investigated phytochemically and only 
6% have been explored pharmaceutically (Cragg and Newman, 2013). The vast ocean 
(covering nearly 70% of the earth’s surface) and its countless, unique marine plants and 
microorganisms remain virtually uncharted as sources for novel medicines (Cragg and 
Newman, 2013). With the advent of scuba diving techniques, the ocean waters have 
started to become a worthwhile source of novel drugs, with thousands of novel bioactive 
compounds emerging from this marine environment (Cragg and Newman, 2013).	  
Microorganisms, which consist of bacteria, archaea, and almost all protazoa, are also an 
extremely productive source of structurally diverse natural products and have produced 
drugs that are prevalent in the pharmaceutical industry. Anti-bacterial agents such as 
penicillins and cephalosporins are derived from the species of microorganisms 
Penicillium and Cephalosporim acremonium, respectively (Fig. 3) (Cragg and Newman, 
2013). Microorganisms have also yielded other products including immunosuppressive 
agents, cholesterol lowering agents, and antiparasitic drugs (Cragg and Newman, 2013).   
                                           
Chemical structure of penicillin core  
Figure 3 
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   While natural products remain a vital component in novel drug discovery, the 
number of new chemical entities (NCE) discovered in recent years has declined 
significantly (Cragg and Newman, 2013). According to the Food and Drug 
Administration, a new chemical entity is a “drug that contains no active moiety that has 
been approved by FDA” (FDA). From 2001-2010, an average of 23 NCE’s were 
discovered per year, down approximately 62% from the 1980’s (Cragg and Newman, 
2013). Despite innovative chemotype breakthroughs, out of 35,000 plant samples 
processed by the National Cancer Institute (NCI) over a span of twenty years, only two 
compounds became commercial products--paclitaxel being one of them (Cragg and 
Newman, 2013).	  
 Although natural products are invaluable in drug discovery, traditional drug 
innovation has its issues including funding and sustainability. Sources of finance for 
natural product drug discovery are extremely limited. The few large pharmaceutical 
companies that utilize natural products will not even discuss funding unless there is 
activity in a Phase I clinical trial (study conducted to determine drugs various side effects 
and how it is metabolized and excreted), preferably Phase II clinical trial (study to 
determine effectiveness of drug) (Cragg and Newman, 2013; FDA). Some companies 
have opted to employ new, exciting chemical techniques such as combinatorial chemistry 
to produce novel medicines (Cragg and Newman, 2013). Combinatorial chemistry 
requires the synthesis of a large amount of compounds (tens to thousands to millions), 
which are then screened together for specific biological activity (Pandeya and Thakkar, 
2005). These techniques reduce the cost and time associated with creating competitive 
and effectual new drugs (Pandeya and Thakkar, 2005). Despite these advantages, it is not 
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evident that these techniques are more successful than natural product use in drug 
discovery, with very few medicines emerging via combinatorial chemistry (Kingston, 
2012). To compare natural products and products synthesized via combinatorial 
chemistry, a variety of molecular properties were investigated to determine structural 
diversity. These properties included a number of rotatable bonds, degrees of unsaturation, 
atom types, number of chiral centers, and number of rings and chains (Gao, 2010). Based 
on the results of this investigation, it was determined that natural products are 
significantly more diverse than combinatorial compounds (Gao, 2010). Furthermore, 
natural products have superior drug-like properties compared to samples of compounds 
synthesized by combinatorial chemistry (Kingston, 2012).  
 Because the earth’s resources are limited, long-term sustainability is also an 
important issue when dealing with plant-based traditional medicines. Although there are 
undoubtedly enough resources for the current provision of natural and synthetic drugs, 20 
or 30 years from now those resources will most likely not be available or affordable for a 
rapidly rising universal population (Cordell and Colvard, 2012). With climate change, 
deforestation in biologically diverse areas, and indiscriminate collection and 
overharvesting of plant samples, many important medicinal plants are under threat, or in 
extreme cases, no longer available (Cordell and Colvard, 2012). Because of this, access 
to medications has become a worldwide concern, with record supply shortages of anti-
cancer drugs reported by the FDA for the United States in 2011 (Cordell and Colvard, 
2012). To address supply problems inherent with plant materials, researches must exploit 
species with similar chemical properties or attempt to produce the product semi-
synthetically (Cragg and Newman, 2005).   
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 Despite declining interests and issues with funding and sustainability, it is 
undeniable that natural products have had a significant impact in the discovery of novel 
drugs. Not only are natural products the forebears of many anti-cancer drugs, they have 
also been important in therapeutic areas such as cholesterol management, arthritis, 
diabetes, and depression (Rouhi, 2003). Barry A. Berkowitz, vice president at Albany 
Molecular Research, comments on the importance of natural products, stating, “We 
would not have the top-selling drug class today, the statins; the whole field of angiotensin 
antagonists and angiotensin-converting-enzyme inhibitors; the whole area of 
immunosuppressives; nor most of the anticancer and antibacterial drugs. Imagine all of 
those drugs not being available to physicians or patients today" (Cragg and Newman, 
2013). 
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II. Terrestrial plants of the genus Perovskia 
 
 The genus Perovskia belongs to the Family Labiatae, Order Lamiales, Class 
Magnoliopsida, and is made up of seven different species (Perveen et al., 2009). Native 
to Central Asia, Afghanistan, Iran, and Pakistan, the plants comprising the Perovskia 
genus are aromatic sub-shrubs featuring extremely branched stems, paniculate leaves, and 
small flowers (Saleem, 2000). The most common species are Perovskia artemisoides, 
Perovskia artiplicifolia, and Perovskia abrotanoides (Saleem, 2000).  
 Various phytochemical studies focusing on secondary metabolites have been 
performed on species in the genus Perovskia. This genus has been found to be a source of 
a variety of secondary metabolites, including essential oils and terpenoids. Many species 
produce volatile oils that exhibit antibacterial activity (Beikmohammadi, 2011). 
Pentacyclic triterpenoids of ursane, oleane and lupane skeleton are usually isolated from 
plants of Perovskia species, such as; germanicol 2, lupeol 3, oleanolic acid 4, and β-
amyrin 5, peradione 6 and sterols like: β-sitosterol 7 and stigmasterol 8 (Fig. 2), have 
been isolated from the members of the Perovskia genus. Sesquiterpenoids such as 
betulenol 9 and α-aromdendrene 10 have also been reported in this genus (Saleem, 2000) 
(Fig. 4).  
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Chemical structure of some terpenoids and sterols isolated from Perovskia species 
 
Figure 4 
 
 Species within the Perovskia genus have myriad of uses. In Pakistan, Perovskia 
abrotanoids is utilized as a refrigerant; in China, the species is employed in treating 
atherosclerosis, cardiovascular diseases, and liver fibrosis (Beikmohammadi, 2011). The 
sap of Perovskia abrotanoides and Perovskia artemisioides has even been utilized to treat 
leishmaniasis, a skin disease caused by protozoan parasites, due to the presence of 
abundant amounts of fat-soluble leishmanicidal constituents found in the roots of the 
plants (Sairafianpour et al., 2001).  
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III. Terrestrial plant Perovskia atriplicifolia, “Russian Sage” 
 
 
 
Photo of Perovskia atriplicifolia 
 
Courtesy of Prescott Park 
 
Figure 5 
 
 Perovskia atriplicifolia, more commonly known as Russian Sage, is a silver-grey 
shrubby plant originating and flourishing in the rocky areas of Pakistan, Afghanistan, 
Iran, and Tibet (Zamfirache et al., 2011). The ornamental plant reaches about 1.5 meters 
high and is comprised of airy spires that bear small, edible lavender flowers (Zamfirache 
et al., 2010). Like other species located in the Lamiaceae plant family, Perovskia 
atriplicifolia possesses glandular secretory trichomes (hairs) positioned on its aerial 
vegetative organs that produce essential oils (Saleem, 2005). Various studies have been 
performed to determine the chemical composition of the oil. According to Jassbi et al. 
(1999), almost 50% of the oil is comprised of monoterpenes, δ-3-carene 11 and 
eucalyptol 12 (1,8-cineole). Boz et al. (2011) found the oil to be comprised mainly of 
limonene 13 (18%), cymene 14 (18%), borneol 15 (15%), cis-β-ocimene 16 (8%), and γ-
terpinene 17 (7%) (Fig. 6).  
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Major monoterpenes identified in P. atriplicifolia 
 
Figure 6 
 
The extremely aromatic volatile oil has been utilized medicinally as a sedative, febrifuge, 
expectorant, analgesic, and antibacterial drug (Boz et al., 2011). Secondary metabolites 
extracted from the Russian sage plant have been found to fight virosis, specifically 
Perovskatone A 18 (Fig. 7), a novel terpenoid that exhibits superior inhibitory hepatitis B 
virus activity in vitro (Jiang et al., 2013).  
 
Perovskatone A isolated from P. atriplicifolia 
 
Figure 7 
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 Despite its medicinal application, Perovskia atriplicifolia is mainly known for its 
ornamental and flavoring qualities and is also smoked as a euphoriant (Zamfirache et al., 
2011). Recently, the Russian sage plant is being explored as a possible remediative plant 
as a means to improve air and soil quality (Zamfirache et al., 2011). P. atriplicifolia 
possesses many characteristics that qualify it as a remediate plant including: high rates of 
growth (even in highly polluted, dry areas), pest resistance, good germination, and heavy 
metal and radioactivity resistance (Zamfirache et al., 2011). Because of its ability to 
tolerate and accumulate heavy metals without transferring these toxic substances to its 
essential oils, P. atriplicifolia can help clean up contaminated soil areas without 
significant yield reduction (Zamfirache et al., 2011). Furthermore, the presence of 
monoterpenes, which are known for their aerosol emitting capacity, in the volatile oil of 
P. atriplicifolia allows the plant to improve the ambient air quality (Zamfirache et al., 
2011). In this thesis, we sought to investigate P. atripliciolia because of its abuse in other 
countries for its psychotropic effects. Plant samples were collected from various parts of 
the world including Pakistan.  Due to the abuse of these plants, we investigated the 
biological effects of their secondary metabolites. Extracts that demonstrated a desired 
biological activity profile were subjected to bioassay-guided fractionation. The bioassays 
included receptor-binding studies for receptors in the cannabinoid and opioid classes. The 
secondary metabolites that possessed strong binding affinity were subjected to 
spectroscopic evaluation in order to elucidate their chemical structures.  
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IV. Opioid and Cannabinoid Receptors 
 Opioid and cannabinoid receptors are G-protein coupled receptors and are located 
mainly within the central nervous system (CNS) (Gao et al., 2011). G-protein coupled 
receptors (GPCRs) are a group of signaling receptors that are involved in the recognition 
and transduction of messages across a membrane (Bockaert and Pin, 1999). Located only 
in eukaryotes including plants, animals, and yeast, GPCRs are the most profuse receptor 
type in the human body and have been involved extensively in drug therapy (Gao, 2010). 
A variety of different ligands, ranging from neurotransmitter to hormones, bind to and 
active the g-protein receptors (Gao, 2010). Various subtypes of opioid and cannabinoid g-
protein receptor systems have been recognized; the opioid receptor system involved 
mainly µ (mu), κ (kappa), and δ (delta) receptors, while the cannabinoid receptor system 
includes CB1 and CB2 receptors. Agonists of opioid and cannabinoid receptors are known 
to produce powerful analgesia and have been explored pharmacologically for the 
treatment of various neuropathic pains (Gao et al., 2011).  
 
IV.1 Opioid Receptors and Ligands 
 Opium, an opioid receptor agonist acquired from the poppy Papaver somniferum, 
has been utilized medicinally as an analgesic and anti-diarrheal drug for more than 5000 
years (Dhawan et al., 1996). Even Hippocrates, the famous ancient Greek physician, 
acknowledged the therapeutic benefits of the poppy extract (Dhawan et al., 1996). In 
1805, morphine, the prominent psychoactive element in opium, was isolated and used in 
pain modulation therapy (Dhawan et al., 1996). Despite its effectiveness as an analgesic, 
morphine and many of its subsequent derivatives have the potential for detrimental side 
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effects such as respiratory depression, constipation, tolerance and abuse (Ananthan, 
2006). The human brain, specifically the hypothalamus and pituitary glands, also 
produces endogenous opioids during pain, excitement, and even strenuous exercise 
(Koneru et al., 2009). Both exogenous opiates (opium and morphine) and endogenous 
opioid peptides (endorphins) have helped localize opioid system receptors in the human 
body (Dhawan et al., 1996). Many other opioid agonists and antagonists have been 
identified (Fig. 8).  
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Selective opioid receptor agonists and antagonists 
Figure 8 
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IV.2 Opioid Receptor Subtypes 
 
 As mentioned previously, opioid receptor systems are comprised of at least three 
subtypes: µ, κ, and δ receptors. Each receptor is named based on its affinity towards a 
specific ligand (Table 1). The µ receptor is characterized by its acute affinity to 
morphine, while κ and δ receptors have high affinities for ketocyclazocine and 
enkephalins, respectively (Koneru et al., 2009).  
 
Table 1: Selective opioid receptor ligands (Gao, 2010)	  
Receptor Endogenous peptides Agonists Antagonists 
µ Endomorphin  Cyprodime (2) 
  Dermorphin Morphine (1) Naloxonazine (3) 
  β-endorphin    
  β-neoendorphin     
δ Leu5-Enkephalin BW373U86 (7) Naltriben (8) 
  Met5-Enkephalin  Naltrindole (9) 
  Deltorphin   
κ Dynorphin A Bremazocine (4)  
  Dynorphin B Ketocyclazocine (5) Nor-binaltorphimine (6) 
  α-neoendorphin    
 
 
Although some opioid receptors are located in the peripheral nervous system, the 
majority accumulate in regions of the central nervous system associated with noxious 
sensory input: the spinal cord, brainstem, medial thalamus, hypothalamus, and limbic 
system (Koneru et al., 2009). Upon activation, opioid receptors can produce analgesia via 
an inhibitory mechanism (Koneru et al., 2009). When an agonist binds to an opioid 
receptor (consisting of seven trans-membrane proteins) (Fig. 9) on a presynaptic neuron, 
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two major changes occur within the neuron: calcium channels are closed and potassium 
channels are opened (Koneru et al., 2009). These changes lead to neuronal 
hyperpolarization, presynaptic inhibition, and eventually a decrease in neurotransmitter 
release into the synaptic cleft (Koneru et al., 2009). 
 
 
      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9 
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IV.3 µ Opioid Receptor (MOR) 
 The µ-opioid receptors (MOR) are a class of opioid receptors which have high 
affinity for the exogenous agonist morphine and endogenous opioids such as 
endomorphin and dermorphin (Gao, 2010). The µ receptor is located in the brain 
(laminae III and IV of the cortex, thalamus, periqueductal gray), and spinal cord 
(substantia gelatinosa) (Koneru et al., 2009). Upon activation, the µ receptor causes 
supraspinal analgesia, physical dependence, respiratory depression, miosis, euphoria, and 
reduced gastrointestinal motility (Koneru et al., 2009). Two subtypes of µ receptors have 
been identified, µ1 and µ2 (Koneru et al,. 2009).  
 
IV.4  κ Opioid Receptor (KOR) 
 The κ opioid receptors (KOR) are a class of opioid receptors which have high 
affinity toward endogenous dynorphins and the exogenous agonist Ketocyclazocine (Gao, 
2010). KORs are located in the brain (hypothalamus, periaqueductal gray, and 
claustrum), spinal cord (substantia gelatinosa), and in pain neurons (Gao, 2010). κ 
receptor activation causes spinal analgesia, sedation, miosis, and inhibition of antidiuretic 
hormone release (ADH) (Koneru et al., 2009). Because of their psychotogenic and 
dysphoric central effects, KORs are primarily utilized as peripheral analgesics (Ananthan, 
2006). Currently, very few pharmacologic drugs on the market target κ receptors (Gao, 
2010). Two subtypes of KORs have been identified, κ1 and κ3 (Koneru et al., 2009).  
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IV.5 δ Opioid Receptor (DOR) 
 The δ opioid receptors (DOR) are a class of opioid receptors which have a high 
affinity for endogenous enkephalins (Gao, 2010). Currently, two subtypes of DORs have 
been identified, DOR1 and DOR2 (Rijn et al., 2013) δ opioid receptors are located in the 
brain (pontine nucleus, amygdala, olfactory bulbs, deep cortex) (Koneru et al., 2009). 
Upon activation, DORs cause euphoria, physical dependence, and analgesia (Koneru et 
al., 2009). Because of their analgesic and euphoric properties, DORs have been 
considered as a potential drug target to treat pain, depression, and anxiety disorders (Rijn 
et al., 2013). Additionally, DORs are known to modulate ethanol and food consumption 
(Rijn et al., 2013). Despite their ability to modulate many physiological responses, only a 
small number of DOR-selective drugs are in clinical trials, and no DOR-selective drugs 
have been approved by the FDA (Rijn et al., 2013).  
 
Figure 10 
 
 
 
IV.6 Other Opioid Receptors  
Other than the µ, δ, and κ opioid receptors, a variety of other opioid receptors 
have been identified. The nociceptin opioid receptor (NOR) is a g-protein coupled 
receptor that was discovered recently in 1994 (Gao, 2010). It is located in many regions 
of the brain, including the cortical areas, olfactory regions, and thalamus, and in the 
spinal cord (Gavioli and Calo, 2013). The endogenous peptide ligand associated with the 
NOR is nociceptin, also known as orphanin FQ (Redrobe, 2002). Nociceptin has been 
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associated with responses dealing with pain, fear and anxiety, learning, memory, feeding, 
drug addiction, and circadian rhythms (Redrobe, 2002).  
The opioid growth factor receptor (OGFr), also known as the ζ (zeta) receptor, a λ	  
(lambda) receptor, and a β-endorphin-sensitive ε (epsilon) opioid-binding site have also 
been identified (Waldhoer, 2004). Despite their identification, little is known about the 
characterization of these receptors, and evidence of their existence through identification 
of their genes is deficient (Waldhoer, 2004).  
 
IV.7 Structure of Opioid Receptors 
  Opioid receptors belong to the Rhodopsin family of the g protein-coupled 
receptors (Gao, 2010). Each opioid receptor includes an intracellular C-terminal tail, 
seven transmembrane helical domains, and an extracellular N-terminal domain (Gao, 
2010). This intricate formation allows for the binding of a variety of endogenous and 
exogenous opioid ligands (Gao, 2010). The µ, δ, and κ opioid receptors are relatively 
similar in structure, with about 60% overall likeness and the greatest homology in the 
seven transmembrane helical domains (Gao, 2010).  
 
IV.8 Cannabinoid Receptors and Ligands 
  
 The discovery of another class of G-protein coupled receptors, cannabinoid 
receptors, stemmed from the desire to comprehend the effects of Δ9-tetrahydrocannabinol 
19 (THC, Fig. 11), the primary psychoactive constituent of marijuana (Cannabis sativa) 
(Mackie, 2008).  
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Chemical structure of Δ9-tetrahydrocannabinol (THC). 
Figure 11 
Interest in the medicinal properties of Cannabis sativa began thousands of years ago, 
around 2600 BCE, when the people of China used the plant for the relief of cramps, 
rheumatic pain, and menstrual pain (Gao, 2010). Despite its utilization for many years, 
the marijuana plant was not scientifically studied in the Western world until the 
nineteenth century (Gao, 2010). In 1964, THC was first isolated by Yechiel Gaoni and 
Raphael Mechoulam of the Weizmann Institute of Science in Rehovot, Israel (Gao, 
2010). Currently, two pharmacologic drugs based on THC are being used clinically.  
Nabilone (12) is a synthetic THC analogue and is given to cancer and AIDs patients to 
combat nausea and as an appetite-stimulant (Gao, 2010). Dronabinol (II), a drug that 
contains synthetic THC, is also utilized in the treatment of nausea and appetite 
stimulation in AIDS-related anorexia (Gao, 2010).  
 The human body also produces endogenous cannabinoids. Anandamide (15) and 2-
arachidonoylglycerol are the two most examined endocannabinoids (16) (Gao, 2010). 
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Cannabinoid receptor agonists and antagonists 
Figure 12 
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IV.9 Cannabinoid Receptors  
 In 1988, Allyn Howlett et al. definitively established the existence of cannabinoid 
receptors and further characterized a possible mechanism (Mackie, 2008).  The majority 
of cannabinoid receptors are located in areas of the brain associated with movement, 
cognition, and sensory functions (Glass et al., 1997). The high density of receptors in 
these regions of the brain correlates with the widespread effects of cannabinoids which 
include: augmentation of the senses, altered emotions, errors in judgment of time and 
space, impulses, hallucinations, and decreased motor activities (Glass et al., 1997).  
 
IV.9 Cannabinoid Receptor Subtypes 
 Agonists of cannabinoid receptor systems can bind to at least two receptor types in 
mammalian tissues: CB1 and CB2. CB1 receptors are located primarily at nerve terminals, 
while CB2 receptors have a more restricted distribution in immune cells and a few 
neurons (Mackie, 2008). When cannabinoid receptors are activated, neuronal excitability 
and the amount of neurotransmitter released into the synaptic cleft is decreased (Mackie, 
2008). Like ligands of opioid receptors, ligands of cannabinoid receptors have therapeutic 
capability including the treatment of inflammation and neuropathic pain (Pertwee, 2006). 
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IV.10 CB1 Receptor 
 CB1 receptors are found predominately on nerve terminals in the brain, with high 
levels associated with the hippocampus, in basal ganglia output nuclei (globus pallidus 
and substantia nigra), and the cerebellum (Fig. 13) (Gao, 2010). The locations of CB1 
receptors are consistent with the known behavioral and physiological effects (diminished 
short term memory, anxiety, and altered locomotion) of cannabinoids such as THC (Gao, 
2010). Although they are most prominent in the CNS, CB1 receptors have also been 
reported in peripheral tissues such as fat (adipocytes), the pancreas, the liver, and skeletal 
muscle (Mackie, 2008). CB1 receptor agonists demonstrate therapeutic capability. 
Inflammation, neuropathic pain, nausea, certain types of cancer, glaucoma, and motor 
dysfunction associated with multiple sclerosis and spinal cord injury can be treated with 
agonists of CB1 receptors (Pertwee, 2006). Furthermore, CB1 receptor agonists can be 
utilized as appetite stimulants (Pertwee, 2006).  
 
Figure 13 
IV.11 CB2 Receptor 
 CB2 receptors are located primarily in immune cells such as T cells, B cells, 
macrophages, and hematopoietic cells (Gao, 2010). Although less prevalent, CB2 
receptors are also present in keratinocytes (Gao, 2010). Evidence suggests that CB2 
receptor agonists can treat neuropathic pain and inflammation, however, their role still 
remains unclear (Pertwee, 2006). 
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IV.12 Structure of Cannabinoid Receptors  
 Like other g-protein coupled receptors, CB1 and CB2 receptors consist of seven 
transmembrane domains, an intracellular C-terminal, and an extracellular N-terminal 
(Galiegue et al., 1995). The amino acid sequences of CB1 and CB2 receptors are about 
44% similar (Gao, 2010). 
Figure 14 
IV.13 Cannabinoid Receptors in Drug Discovery 
 Evidence suggests that the endocannabinoid system is involved in a variety of 
human health problems. Agonist and antagonists of the cannabinoid system have 
demonstrated promising treatment against obesity, neurodegeneration, treatment of drug 
abuse, neuropathic pain, and even cancer (Gao, 2010).  
IV.13.1 CB1 Receptor and Obesity 
 Obesity is an extremely prevalent health issue that causes other severe problems 
including diabetes, cardiovascular diseases, and some cancers (Gao, 2010). More than 
70% of people in the United States and the United Kingdom suffer from obesity 
according to the World Health Organization (WHO) (Gao, 2010). Although significantly 
altering lifestyle and diet can manage and treat obesity, many researchers are attempting 
to develop drugs to combat the debilitating disease. As mentioned previously, CB1 
agonists have the potential to act as appetite stimulants (Pertwee, 2006). Therefore, 
current studies support the concept that antagonists of CB1 receptors can lead to long-
term weight loss and improve lipid metabolism (Gao, 2010). Because of the severe side 
effects of CB1 drugs acting in the CNS (depression, anxiety, stress disorders), researchers 
are attempting to target CB1 receptors that are located in the peripheral system (fat and 
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liver) to alleviate the harmful side effects (Gao, 2010). 
IV.13.2 CB1 Receptor and Neurodegenerative Diseases  
 Neurodegenerative diseases such as Huntington’s disease, Parkinson’s disease, 
Alzheimer’s disease, multiple sclerosis, and epilepsy involve the loss of structure or 
function and final death of neurons (Tian et al., 2014). Because of their prevalence and 
localization in the brain, CB1 receptors and agonists have been studied to determine their 
relationship with neurodegenerative diseases (Gao, 2010). For example, it is accepted that 
one of the earliest molecular changes known in human Huntington’s disease is associated 
with the loss of CB1 receptors in certain parts of the brain (globus pallidus and striatum) 
(Gao, 2010). In patients with Alzheimer’s disease, abnormal CB1 and CB2 receptors were 
highly expressive near the senile plaques associated with the disease (Gao, 2010). 
Although there is evidence supporting the relationship between CB receptors and 
neurodegenerative diseases, much more research must be conducted to understand the 
roles of the cannabinoid system in these diseases.  
IV.13.3 CB1 Receptors and Drug Abuse 
 The endocannabinoid receptor system has been closely linked to drug abuse, and 
CB1 receptor antagonism has been shown to decrease the craving for certain drugs 
including alcohol and cigarettes (Gao, 2010).  For example, blocking CB1 receptors 
causes a decrease in the consumption of alcohol, while activation of the receptors results 
in increased alcohol consumption (Gao, 2010). Furthermore, a 10 week clinical trial 
demonstrated positive results when using CB1 antagonists to suppress smoking cravings 
(Gao, 2010). During the trial, participants (moderate cigarette smokers) took a CB1 
antagonist drug (rimonabant) and experienced increased abstinence from smoking 
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compared to participants who took a placebo (Gao, 2010). Although there are positive 
outcomes resulting from the blockage of CB1 receptors, it has yet to be determined if the 
antagonism will be an effective long-term approach for the treatment of craving disorders 
(Gao, 2010).  
 
IV.13.4 CB1 and CB2 Receptors and Neuropathic Pain 
 Neuropathic pain	  is	  defined as ‘‘initiated or caused by a primary lesion or 
dysfunction in the nervous system’’ according to the International Association for the 
Study of Pain (IASP) (Dworkin et al., 2007). Neuropathic pain affects millions of people 
all over the world and is caused by a variety of problems including diabetic neuropathy, 
multiple sclerosis, nerve compression syndromes, stroke, spinal cord injury, and cancer 
(Gao, 2010). Treatment of neuropathic pain is complex and is accompanied by many 
adverse side effects (Dworkin et al., 2007). The cannabinoid system is known to be 
associated with pain modulation (Ikeda et al., 2013). CB1 receptor activation in the CNS 
and peripheral tissues has been shown to inhibit pain responses (including neuropathic 
pain) and suppress inflammatory hypersensitivity (Ikeda et al., 2013). Because of their 
distribution in the brain, however, CB1 receptor agonists have produced negative side 
effects such as depression and anxiety (Ikeda et al., 2013). CB2 receptor agonists, located 
predominantly in spinal cord, have also been shown to reduce neuropathic pain and 
inflammation (Gao, 2010).  
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IV. 13.5 CB1 and CB2 Receptors and Cancer 
 Although CB1 and CB2 receptor agonists were found to inhibit tumor growth in 
certain cancers in 1975, the mechanism of the agonists and their anticancer activity was 
not studied until recently (Gao, 2010). It has been discovered that CB1 and CB2 receptor 
ligands inhibit the growth of cancer cells and reduce cancer cell viability through a 
variety of mechanisms including mitosis and apoptosis (Gao, 2010).   
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Materials and Methods: 
 
I. General experimental procedures 
1H and 13C Nuclear Magnetic Resonance (NMR) spectra were obtained on Bruker 
model AMX 500 NMR and 400 Avance NMR spectrometers with standard pulse 
sequences, operating at 500 MHz and 400 MHz, respectively in 1H and 100 MHz and 125 
MHz in 13C, respectively. The chemical shift values were reported in parts per million 
units (ppm) from trimethylsilane (TMS) using known solvent chemical shifts. Coupling 
constants were recorded in Hertz (Hz). Standard pulse sequences were used for 
Correlation Spectroscopy (COSY), Heteronuclear Multiple Quantum Coherence 
(HMQC), Heteronuclear Multiple Bond Coherence (HMBC), Total Correlated 
Spectroscopy (TOCSY), Nuclear Overhauser Effect Spectroscopy (NOESY) and 
Distortionless Enhancement by Polarization Transfer (DEPT). High-resolution mass 
spectra (HRMS) were measured on a Micromass Q-Tof Micro mass spectrometer with a 
lock spray source. Column chromatography was carried out on silica gel (70-230 mesh, 
Merck), SPE reverse phase C-8 column and Sephadex LH-20 (Mitsubishi Kagaku, 
Tokyo, Japan). TLC (silica gel 60 F254) was used to monitor fractions from column 
chromatography. Visualization of the TLC plates was achieved with a UV lamp (λ = 254 
and 365 nm) and anisaldehyde/acid spray reagent (MeOH-acetic acid-anisaldehyde-
sulfuric acid, 85:9:1:5). Solvents were certified grade for Fischer Scientific. All 
chemicals used were purchased from Sigma-Aldrich (St. Louis, Mo) with the following 
exceptions: for the binding experiments, [3H]-CP-55,940 (144 Ci/mmol), was purchased 
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from Perkin-Elmer Life Sciences Inc. (Boston, MA, U.S.A.). CP-55,940 was purchased 
from Tocris Bioscience (Ellisville, Missouri, U.S.A.). 
II. Plant material 
The plant Perovskia atriplicifolia was collected in the region of Quetta, Pakistan 
in July of 2012 and identified by Dr. Arsala Mansoor from the Medicinal Plant Garden at 
the University of Balochistan, Quetta, Pakistan. A voucher specimen (UM 072012) has 
been deposited in the culture collection of the Department of Medicinal Chemistry, 
University of Mississippi. The plant material was separated into three parts: leaves, stems 
and roots. 
 
III. Extraction and isolation 
The dried plant material was ground into a powder yielding 370 g (leaves), 200 g 
(stems) and 120 g (roots), then the different parts of the plant were extracted with ethanol 
after maceration for three days, separately. Removal of the solvent afforded a viscous 
residue of 39.5 g (leaves), 6.22 g (stems) and 1.44 g (roots). The ethanolic extract from 
leaves showed moderate radioligand displacement binding affinity for opioid receptors 
(42.8 % for δ and 52.5% for µ). The ethanolic extract (39.5 g) was chromatographed on 
Silica gel flash column with stepwise fractions from hexanes to methanol, yielding five 
fractions (100% hexane, 100% dichloromethane, 100% EtOAc, 80% EtOAc in MeOH, 
and 100% MeOH). The EtOAc fraction showed strong binding affinities for δ opioid 
receptors (88.4 %), and this fraction was chromatographed on a SPE silica gel reverse 
phase column C-8, eluted with water- methanol to yield six fractions (100% water, 80 % 
water in methanol, 60 % water in methanol, 40% water in methanol, 20% water in 
	  32	  
methanol, 100% methanol); all fractions were submitted for opioid binding activity. The 
fourth (40% water in methanol) and fifth (20% water in methanol) fractions showed 
strong binding affinities for δ opioid receptors with values of 62.8 % and 78.5 %, 
respectively. The fourth fraction (40% water in methanol) was rechromatographed in 
silica gel column eluted with hexane to EtOAc in step gradient to yield fifteen 
subfractions, and these were combined based on the TLC (CH2Cl2/EtOAc; 8:2). A 
precipitate was obtained from subfractions 10 and 12 and crystallized separately to obtain 
the flavones: 5-hydroxy-3’,4’,6,7-tetramethoxy flavone (Compound A) and 5,7-
dihydroxy-3’,4’,6,-trimethoxy flavone (Compound B), respectively. The fifth fraction 
(20% water in methanol) was rechromatographed in silica gel column eluted with hexane 
to EtOAc in step gradient to yield thirteen subfractions. A precipitate was also obtained 
from subfractions 5-7. Based on TLC (CH2Cl2;/EtOAc; 8:2), two major spots were found 
in all the precipitates, which were combined and subject to a column of Sephadex LH-20 
eluted with CH2Cl2/MeOH (1:1) to furnish 5-hydroxy-4’,6,7-trimethoxy flavone 
(Compound C) and 5,7-dihydroxy-4’,6-dimethoxy flavone (Compound D). All purified 
compounds were submitted for opioid binding affinity. 
 
IV. Cell culture 
Human Embryonic Kindney-293 (HEK-293) cells stably transfected with opioid 
receptor subtypes µ, δ, and κ were used to perform the opioid receptor binding assays. 
These cells were maintained at 37°C and 5% CO2 in a Dulbecco’s modiﬁed Eagle 
medium (DMEM) nutrient mixture supplemented with 2 mM L-glutamine, 10% fetal 
bovine serum, penicillin−streptomycin, and either G418 or hygromycin B antibiotic 
	  33	  
solutions. Membranes for the radioligand binding assays were prepared by scraping the 
cells in a 50 mM Tris-HCl buﬀer, followed by homogenization, sonication, and 
centrifugation for 40 min at 13650 rpm at 4°C. These were kept at -80 °C until used for 
bioassays. Protein concentration was determined via Bio-Rad Protein Assay (Bradford, 
1976). 
V. Radioligand Binding for Cannabinoids and Opioid Receptor Subtypes 
All the fractions and pure compounds from P. atriplicifolia were run in 
competition binding assays against both cannabinoid receptor subtypes and all three 
opioid receptor subtypes (León et al., 2013). Cannabinoid binding took place under the 
following conditions: 10 µM of each compound was incubated with 0.6 nM [3H] CP 
55.940 and 10 µg of CB1 or CB2 membranes for 90 minutes in a silanized 96-well plate. 
The reaction was terminated via rapid vacuum ﬁltration through GF/B ﬁlters presoaked 
with 0.3% bovine serum albumin (BSA) using a Perkin-Elmer 96-well Uniﬁlter followed 
by 10 washes with 50 mM Tris-HCl. Plates were read using a Perkin-Elmer Topcount. 
Opioid binding assays were performed under the following conditions: 10 µM of each 
compound was incubated with [3H]-DAMGO (µ), [3H]-U-69,593 (κ), or [3H]-enkephalin 
(δ) for 60 min in a 96-well plate. Percent binding was calculated as the average of the 
triplicate tested at 10 µM. Each sample concentration point of the compounds tested in 
dose response was in triplicate, and each compound showing activity was tested at least 
three times. The reaction was terminated via rapid vacuum ﬁltration through GF/B ﬁlters 
presoaked with 0.3% bovine serum albumin (BSA) using a Perkin-Elmer 96-well 
Uniﬁlter followed by 10 washes with 50 mM Tris-HCl. Plates were read using a Perkin-
Elmer Topcount. Total binding was deﬁned as binding in the presence of 1.0% DMSO. 
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Nonspeciﬁc binding was the binding observed in the presence of 10µM DAMGO (µ), 
nor-binaltorphimine (κ), or DPDPE (δ). Speciﬁc binding was deﬁned as the diﬀerence 
between total and nonspeciﬁc binding. Percent binding was calculated using the 
following formula:  (binding of compound - nonspecific binding) x 100/specific binding. 
 
 
 
Results: 
I. Extraction and Initial Bioassay-guided Fractionation  
 The powdered sample (370 grams) of Perovskia atriplicifolia leaf was extracted in 
ethanol, yielding 39.57 grams of extract.  The powdered sample of the plant stem (200 
grams) and root (120 grams) were also extracted in ethanol, yielding 6.22 grams and 1.44 
grams, respectively. The extracts were sent to the lab to test radioligand displacement 
binding affinity for opioid receptors and cannabinoid receptors. The leaf extract exhibited 
the best radioligand displacement affinity of opioid receptors, selectively inhibiting 
42.8% of specific binding of δ receptors, 37.6% of κ receptors, and 52.5% of µ receptors. 
Because of this activity, the extract was further subjected to silica gel vacuum liquid 
chromatography (VLC) in silica flash, which resulted in five fractions. These fractions 
were also submitted for assay and their activities are shown in the figure 15, as well as 
their weights. 
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Initial steps and activity for P. atriplicifolia 
Figure 15 
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II. Isolation and Purification/biological evaluation 
 The initial fractions were tested for their binding against opioid and cannabinoid 
receptor subtypes, and the EtOAc fraction selectively inhibited 88.4% of the specific 
binding of δ opioid receptors. The EtOAc fraction was then subjected to reversed-phase 
chromatography and yielded six fractions, which were also tested for opioid and 
cannabinoid receptor competitive binding (Fig. 16). 
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Fractionation of P. atriplicifolia 
Figure 16 
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Fraction 4 was rechromatographed on silica gel column in a gradient step, increasing 
polarity starting with hexane to 100% EtOAC and 25 fractions were obtained. When 
these fractions were compared to TLC (CH2Cl2/EtOAc; 8:2) (Fig. 17), they were 
combined to yield 13 different fractions.  
 
TLC plate for fraction 4 
Figure 17 
Subfractions 10-12 were submitted for biassays, and subfractions 10 and 11 showed a 
high affinity for δ opioid receptors. (Table 2) 
Table 2. % of displacement of radioligands for subfractions obtained for fraction 4 of P. 
atriplicifolia. 
 
 CB1 
%inhibition 
CB2 
%inhibition 
Delta 
%inhibition 
Kappa 
%inhibition 
Mu 
%inhibition 
Fraction 4 
Subfract. 10 
0.3 4.2 86.0 7.5 9.5 
Fraction 4 
Subfract. 11 
19.7 7.2 84.6 8.6 17.4 
Fraction 4 
Subfract. 12 
22.1 5.4 60.8 27.8 54.3 
Naloxone 
CP55,940 
-- 
104.3 
      -- 
     102.6 
106.40 
-- 
101.59 
-- 
96.95 
-- 
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 A precipitate was obtained from subfractions 10 and 12 and crystallized separately 
to obtain the compounds 5-hydroxy-3’,4’,6,7-tetramethoxy flavone (Compound A) and 
5,7-dihydroxy-3’,4’,6,-trimethoxy flavone (Compound B), respectively.  
 Fraction 5 was subjected to chromatography on silica gel column in a gradient step, 
increasing polarity starting with hexane to 100% EtOAC yielding 25 fractions. When 
these fractions were compared to TLC (CH2Cl2/EtOAc; 8:2), they were combined to 
yield 13 different subfractions that were submitted for bioassays (Fig. 18). 
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Fractionation for fraction 5 of P. atriplicifolia 
Figure 18 
A precipitate was obtained from subfractions 5 to 7, and by TLC (CH2Cl2;/EtOAc; 8:2), 
two major spots were found in all the precipitates; these were combined and subject to a 
column of Sephadex LH-20 eluted with CH2Cl2/MeOH (1:1) to furnish the flavones 5-
hydroxy-4’,6,7-trimethoxy flavone (Compound C) and 5,7-dihydroxy-4’,6-dimethoxy 
flavone (Compound D). The pure compounds were then submitted for bioassays and 
showed 31.6% and 79.9% radioligand displacement affinity of δ opioid receptors, 
respectively. 
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III. Structural Elucidation 
 Compounds 5-hydroxy-3’,4’,6,7-tetramethoxy flavone (Compound A) and 5,7-
dihydroxy-3’,4’,6,-trimethoxy flavone (Compound B) were isolated from the subfraction 
4 as a yellowish, amorphous solid. For Compound A, a flavone skeleton was evident 
from the coupling pattern ABC of the B-ring protons in its 1H NMR spectrum, δH 7.65 
(1H, dd, J = 2.1, 8.5 Hz), 7.52 (1H, d, J = 2.3 Hz) and 7.07 (1H, d, J = 8.6 Hz) and two 
singlets signals at δH 6.95 and 6.88 ppm, corresponding to the protons in C-3 and C-8, 
respectively. The spectrum also showed signals of four methoxy groups between 3.80 to 
3.98 ppm (Fig. 18). 
 
1H NMR spectrum of 5-hydroxy-3’,4’,6,7-tetramethoxy flavone 
Figure 19  
Analysis of the 13C NMR spectrum and DEPT experiments confirmed a flavone moiety 
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with the presence of a typical ketone carbonyl signal at δC 182.6 in total fifteen signals 
plus four additional methyl signals at δC 60.4, 56.8, 56.2, and 56.1 ppm, corresponding 
with the methoxy groups (Fig. 19). 
 
13C NMR spectrum of 5-hydroxy-3’,4’,6,7-tetramethoxy flavone 
Figure 20 
 
The 1H NMR and 13C NMR spectroscopic data were found to be similar to those of 5-
hydroxy-3’,4’,6,7-tetramethoxy flavone (Zhao et al., 2012). The nature and identity of 
this flavone was deduced from the 2D NMR experiments (COSY, NOESY, HMBC, and 
HSQC) which are located in the appendix. 	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5-hydroxy-3’,4’,6,7-tetramethoxy flavone, Compound A 
Figure 21 
 
The 1H NMR spectrum of 5,7-dihydroxy-3’,4’,6,-trimethoxy flavone (Compound B) 
showed absence of one methoxy group, and the spectroscopic data is in agreement with 
reported data from Suleimenov et al., 2005. 1H, 13C NMR, HSQC, and HMBC spectra are 
shown in the appendix. 
	  
5,7-dihydroxy-3’,4’,6,-trimethoxy flavone, Compound B 
Figure 22 
 
Compounds 5-hydroxy-4’,6,7-trimethoxy flavone (Compound C) and 5,7-dihydroxy-
,4’,6,-dimethoxy flavone (Compound D) were isolated from subfraction 5 as a yellowish, 
amorphous solid. For 5-hydroxy-4’,6,7-trimethoxy flavone (Compound C), its 1H NMR 
spectrum showed an AB pattern in ring B of the flavone, corresponding to a 
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monosubstitution in the position 4’, and signals for three methoxy groups (Fig. 22). 13C 
NMR and DEPT spectra are located in the appendix. 
	  
1H NMR spectrum of 5-hydroxy-4’,6,7-trimethoxy flavone 
Figure 23 
 
	  
5-hydroxy-4’,6,7-trimethoxy flavone, Compound C 
Figure 24 
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5,7-dihydroxy-4’,6,-dimethoxy flavone, Compound D, was identified and its structure 
elucidated following the same analysis as the first compound, Compound A (1H NMR, 
13C NMR, and DEPT spectra are showed in the appendix). The spectroscopic data for the 
last compound is in agreement with Horie et al., 1998. 	  
	  
5,7-dihydroxy-4’,6,-dimethoxy flavone, Compound D 
Figure 25 
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Conclusion 
  Plants and their natural products have been an undeniable resource in the 
development of effective novel drugs utilized in the treatment of many human diseases.  
In this thesis, we sought to investigate terrestrial plant Perovskia atripliciolia and the 
biological effects of its secondary metabolites. Extracts that demonstrated good selective 
opioid and cannabinoid receptor binding were subjected to bioassay-guided fractionation. 
The secondary metabolites that possessed strong binding affinity were subjected to 
spectroscopic evaluation in order to elucidate their chemical structures. Four active 
compounds were identified from the crude extract in Perovskia atriplicifolia: 1) 5-
hydroxy-3’,4’,6,7-tetramethoxy flavone, 2) 5,7-dihydroxy-3’,4’,6,-trimethoxy flavone, 3) 
5-hydroxy-4’,6,7-trimethoxy flavone, and 4) 5,7-dihydroxy-4’,6,-dimethoxy flavone.  
Each compound exhibited good selective δ-opioid receptor binding affinity and was 
characterized as a flavonoid, a plant secondary metabolite consisting of three-ring 
structure with various substitutions (Middleton, 2000). Flavonoids have been found in a 
myriad of foods in the human diet, from citrus fruits to nuts to tea and red wine, and the 
compounds are also known to be the pigments responsible for giving leaves their vibrant 
colors in autumn (Middleton, 2000). Although the structures of these four compounds 
were isolated and their chemical structures elucidated, further studies need to be 
performed to determine each compounds mechanism of action, find out how compounds 
fit into receptors, etc. 
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1H NMR spectrum of 5-hydroxy-3’,4’,6,7-tetramethoxy flavone (Compound A) 
Figure A-1 
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1H NMR spectrum of 5-hydroxy-3’,4’,6,7-tetramethoxy flavone (Compound A) (blown 
up version) 
Figure A-2 
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13C NMR spectrum of 5-hydroxy-3’,4’,6,7-tetramethoxy flavone (Compound A) 
Figure A-3 
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DEPT135 spectrum of 5-hydroxy-3’,4’,6,7-tetramethoxy flavone (Compound A) 
 
Figure A-4 
 
 
 
 
 
 
 
 
	  57	  
 
	  
HSQC spectrum of 5-hydroxy-3’,4’,6,7-tetramethoxy flavone (Compound A) 
 
Figure A-5 
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HMBC spectrum of 5-hydroxy-3’,4’,6,7-tetramethoxy flavone (Compound A) 
 
Figure A-6 
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1H NMR spectrum of 5, 7-dihydroxy-3’,4’,6-trimethoxy flavone (Compound B) 
Figure A-7 
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1H NMR spectrum of 5, 7-dihydroxy-3’,4’,6-trimethoxy flavone (Compound B) (blown 
up version) 
Figure A-8 
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DEPT135 spectrum of 5, 7-dihydroxy-3’,4’,6-trimethoxy flavone (Compound B) 
 
Figure A-9 
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HSQC spectrum of 5, 7-dihydroxy-3’,4’,6-trimethoxy flavone (Compound B) 
 
Figure A-10 
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HMBC spectrum of 5, 7-dihydroxy-3’,4’,6-trimethoxy flavone (Compound B) 
 
Figure A-11 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  64	  
 
 
 
 
1H NMR spectrum of 5-hydroxy-4’,6,7-trimethoxy flavone (Compound C) 
Figure A-12 
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13C NMR spectrum of 5-hydroxy-4’,6,7-trimethoxy flavone (Compound C) 
Figure A-13 
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DEPT135 spectrum of 5-hydroxy-4’,6,7-trimethoxy flavone (Compound C) 
Figure A-14 
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1H NMR spectrum of 5, 7-dihydroxy-4’,6-dimethoxy flavone (Compound D) 
Figure A-15 
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13C NMR spectrum of 5,7-dihydroxy-4’,6-dimethoxy flavone (Compound D) 
Figure A-16 
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DEPT135 spectrum of 5,7-dihydroxy-4’,6-dimethoxy flavone (Compound D) 
Figure A-17 
 
 
 
 
